(Q40364429)

19 September 2017

Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas (English)

1 reference

19 September 2017

2

1 reference

19 September 2017

4

Gabor Halmos

1 reference

19 September 2017

1

Gunhild Keller

1 reference

19 September 2017

Attila Nagy

3

1 reference

19 September 2017

Benjamin Baker

series ordinal

5

1 reference

19 September 2017

Jorg B Engel

series ordinal

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

19 September 2017

1 reference

19 September 2017

104

1 reference

19 September 2017

10

1 reference

19 September 2017

2266-2274

1 reference

Therapeutic options in the management of renal cell carcinoma

19 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Renal cell carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Chemotherapy targeted to cancers through tumoral hormone receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Hypothalamic hormones and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Bombesin stimulates growth of human prostatic cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal d-Trp or d-Tpi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21402

1 reference

7 January 2021

Multidrug resistance transporters and modulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Circumvention of multi-drug resistance in human kidney and kidney carcinomain vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21402

7 January 2021

Identifiers

DOI

10.1002/CNCR.21402

1 reference

19 September 2017

1 reference